Breast cancer and melanoma are both cancers for which the FDA has approved targeted therapies based on specific genetic mutations, as noted in [1], [2], and [3]. Furthermore, both conditions are treated using precision medicine approaches [4] and require diagnostic testing for specific gene or protein changes [5].